ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.57 +2.58%

+$0.18 today

Market cap
$6.99B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 11.10M

Average 16.40M

Balance Sheet

Inspect the capital base behind the business.

Assets

$501.90M

FY 2025 · Annual

+31.1% YoY

Liabilities

$1.00B

FY 2025 · Annual

+15.0% YoY

Equity

-$499.57M

FY 2025 · Annual

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents181.1M104.64M265.45M143.43M88.33M
Short-term Investments136.02M2.54M1.01M6.38M154.48M
Net Receivables1.33M1.89M3.17M2.65M42.62M
Inventory0008.27M910K
Other Current Assets2.96M2.9M5.21M1.3M3.89M
Total Current Assets334.35M140.58M294.08M184.59M314.88M
Property, Plant & Equipment (Net)119.17M189.45M182.68M170.46M147.55M
Goodwill000910K910K
Intangible Assets1.42M20M17.09M15.02M13.04M
Long-term Investments7.6M840K891K700K10.48M
Tax Assets00000
Other Non-current Assets6.38M11.49M9.7M11.26M15.05M
Total Non-current Assets134.56M221.78M210.37M198.35M187.02M
Total Assets468.91M362.36M504.45M382.93M501.9M
Account Payables11.42M21.02M9.2M6.73M6.98M
Short-term Debt299.24M431.9M009.29M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities16.52M19.74M18.31M15.98M25.42M
Total Current Liabilities369M500.86M58.28M54.94M61.75M
Long-term Debt306.35M241.27M681.54M461.88M835.16M
Deferred Tax Liabilities162K0000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities249K22.09M310.63M319.42M70.89M
Total Non-current Liabilities343.83M311.32M1.03B816.12M939.72M
Total Liabilities712.82M812.18M1.09B871.06M1B
Common Stock40K42K67K85K101K
Retained Earnings(1.96B)(2.38B)(2.96B)(3.38B)(3.73B)
Accumulated OCI4K183K10K1.2M28.96M
Other Stockholders Equity0000909K
Minority Interest(1.74M)(2.49M)1.05M969K895K
Total Equity(243.91M)(449.82M)(585.94M)(488.13M)(499.57M)
Total Debt645.66M723.77M726.72M504.17M878.12M
Net Debt464.56M619.13M461.27M360.74M789.78M

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$45.1M
Short-term Investments$289.2M
Receivables$53.6M
Inventory$6.0K
Other Current$30.9M
Total Current Assets$418.8M
PP&E (Net)$142.7M
Goodwill$10.8M
Other Non-current$37.2M
Total Non-current Assets$190.6M
Total Assets$609.4M

Analysis

Selected assets total $609.4M for Latest. The largest visible component is Short-term Investments at $289.2M, about 47.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportOct 14, 2026
4Statement of changes in beneficial ownershipOct 6, 2026

How much cash does IBRX have?

ImmunityBio, Inc. (IBRX) reported $88.33M in cash and equivalents in fiscal 2025.

How much debt does IBRX carry?

ImmunityBio, Inc. (IBRX) reported $878.12M of total debt, with net debt of $789.78M.